The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: A randomized, double-blind, placebo-controlled trial

William V. Bobo*, Neil D. Woodward, Min Young Sim, Karuna Jayathilake, Herbert Y. Meltzer

*Corresponding author for this work

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Background: The efficacy, safety and tolerability of adjunctive armodafinil for cognitive performance, and negative and affective symptoms, were examined in 60 patients with schizophrenia or schizoaffective disorder. Method: This was a 6-week, double-blind, placebo-controlled, fixed dose trial of armodafinil (150. mg/d) augmentation in patients with clinically stable schizophrenia or schizoaffective disorder. Cognition, psychopathology, alertness/wakefulness and adverse effects were assessed with standardized rating instruments. The primary endpoint was performance on measures of attention/vigilance. Results: Patients were randomly allocated to adjunctive armodafinil or placebo. There was a significant Drug × Time interaction effect for attention/vigilance, due to modest non-significant worsening in the armodafinil group and improvement in the armodafinil group [CPT-Pairs d', F(1,40) = 6.2, p = 0.017]. However, it became non-significant after correction for multiple comparisons. There were no differences between armodafinil and placebo in other cognitive domains or psychopathology measures. However, armodafinil was associated with significant improvement in the Scale for the Assessment of Negative Symptoms (SANS) anhedonia-asociality [F(1,41) = 4.1, p = 0.05]. Conclusions: There were no significant differences in neurocognitive measures between adjunctive armodafinil and placebo in this 6-week study. Armodafinil improved anhedonia-asociality, but not other negative symptom domains.

Original languageEnglish (US)
Pages (from-to)106-113
Number of pages8
JournalSchizophrenia Research
Volume130
Issue number1-3
DOIs
StatePublished - Aug 1 2011

Keywords

  • Adjunctive treatment
  • Armodafinil
  • Depressive symptoms
  • Negative symptoms
  • Neurocognition
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: A randomized, double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this